<a href="https://www.fiercebiotech.com/biotech/ada-more-cagrisema-weight-loss-data-coming-jury-still-out-amid-tough-retatrutide" hreflang="en">ADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons</a>
Novo Nordisk's CagriSema is being compared to Eli Lilly's retatrutide in the obesity treatment race, with CagriSema showing 23% weight loss in trials, while retatrutide demonstrated a higher 28% weight loss. Despite the early challenges, Novo's CSO remains optimistic about CagriSema's potential and ongoing trials to enhance its effectiveness.
The most valuable insight for a professional in healthtech and biotech is the competitive landscape between Novo Nordisk's CagriSema and Eli Lilly's retatrutide in obesity treatment. While retatrutide shows superior weight loss, the focus is shifting towards factors like tolerability and addressing comorbidities. This signals a strategic opportunity for developing or investing in drugs that balance efficacy with broader health benefits, especially as the market for obesity treatments expands.